Patents by Inventor Shuzhen WANG

Shuzhen WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230153781
    Abstract: A transaction data processing method includes: determining one or more transaction key values and one or more transaction feature values of a to-be-processed transaction according to transaction information of the to-be-processed transaction; determining a rule union corresponding to the to-be-processed transaction according to the one or more transaction key values, the rule union including a plurality of to-be-matched rules; matching the one or more transaction feature values of the to-be-processed transaction sequentially with the plurality of to-be-matched rules in the rule union to obtain a rule matching result of the to-be-processed transaction; and performing a billing process of the to-be-processed transaction according to the rule matching result.
    Type: Application
    Filed: May 10, 2021
    Publication date: May 18, 2023
    Inventors: Zhirong SHEN, Yanming YANG, Jianbin GAO, Rui LI, Shuzhen WANG, Fuyang WEN, Jinfeng JIANG
  • Patent number: 10875903
    Abstract: Bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions are provided. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: December 29, 2020
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Shuzhen Wang, Yijun Chen, Dongyang He, Nan Liu, Chao Ma, Zhenyue Gao
  • Publication number: 20200062818
    Abstract: Bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions are provided. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.
    Type: Application
    Filed: May 5, 2014
    Publication date: February 27, 2020
    Applicant: China Pharmaceutical University
    Inventors: Shuzhen WANG, Yijun CHEN, Dongyang HE, Nan LIU, Chao MA, Zhenyue GAO